Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,886 questions in 74 reviews · Skin

current versions

No studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Anti‐angiogenic drugs plus chemotherapy vs chemotherapy Toxicity (≥ G3) · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 0.68 [0.09, 5.32]	324 participants	Low
Biochemotherapy vs chemotherapy Overall survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.94 [0.84, 1.06]	1317 participants	High
Biochemotherapy vs chemotherapy Progression‐free survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.9 [0.83, 0.99]	964 participants	High
Biochemotherapy vs chemotherapy Tumour response · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 1.36 [1.12, 1.66]	770 participants	High
Biochemotherapy vs chemotherapy Toxicity (≥ G3) · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 1.35 [1.14, 1.61]	631 participants	High
Polychemotherapy vs chemotherapy Overall survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.99 [0.85, 1.16]	594 participants	High
Polychemotherapy vs chemotherapy Progression‐freesurvival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 1.07 [0.91, 1.25]	398 participants	High
Polychemotherapy vs chemotherapy Tumour response · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 1.27 [1.02, 1.58]	1885 participants	Moderate
Anti‐PD1 monoclonal antibodies vs chemotherapy Toxicity (≥ G3) · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	0.55 [0.31, 0.97]	1360 participants	Low
Polychemotherapy vs chemotherapy Toxicity (≥ G3) · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 1.97 [1.44, 2.71]	390 participants	Moderate
Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies Overall survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.63 [0.6, 0.66]	764 participants	High
Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies Progression‐free survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.54 [0.5, 0.6]	1465 participants	High
Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies Tumour response · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 2.47 [2.01, 3.04]	1465 participants	High
Anti‐PD1 monoclonal antibodies vs anti‐CTLA4 monoclonal antibodies Toxicity (≥ G3) · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	RR 0.7 [0.54, 0.91]	1465 participants	Low
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy Overall survival† · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane	HR 0.81 [0.65, 1.01]	1157 participants	Low
Montelukast vs placebo Change (improvement) in disease severity (4 to 8 weeks) SMD (modified EASI score and SASSAD) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	3 studies · 131 participants	Low
Montelukast vs conventional treatment Adverse effects (4 to 6 weeks) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	2 studies · 63 participants	Low
Montelukast vs conventional treatment Requirement for corticosteroid (steroid‐sparingeffect) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs conventional treatment Reduction of pruritus · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs conventional treatment Improvement in quality of life · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs conventional treatment Need for emollient use · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs placebo Effect of long‐term control (> 3 months) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs placebo Adverse effects (4 to 8 weeks) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	3 studies · 131 participants	Low
Montelukast vs placebo Requirement for corticosteroid (steroid‐sparingeffect) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	1 study · 58 participants	Low
Montelukast vs placebo Reduction of pruritus (score range 0 to 10; higher score means better improvement) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	1 study · 58 participants	Low
Montelukast vs placebo Improvement in quality of life · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs placebo Need for emollient use · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Montelukast vs conventional treatment Change (improvement) in disease severity (4 weeks) SCORAD score · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	1 study · 31 participants	Very low
Montelukast vs conventional treatment Effect of long‐term control (> 3 months) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane	no estimate extracted	NR	No studies
Moxifloxacin vs amoxicillin‐clavulanate Mortality · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 3 [0.39, 23.07]	1 study · 54 participants	Very low
Intravenous immunoglobulin vs placebo Serious adverse events (SAE) · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 0.73 [0.32, 1.65]	1 study · 100 participants	Low
Intravenous immunoglobulin vs placebo Survival time · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	1 study · 100 participants	Low
Intravenous immunoglobulin vs placebo Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	NR	No studies
Moxifloxacin vs amoxicillin‐clavulanate Serious adverse events (SAE) · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 0.63 [0.3, 1.31]	1 study · 54 participants	Very low
Moxifloxacin vs amoxicillin‐clavulanate Survival time · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	1 study · 54 participants	Very low
Moxifloxacin vs amoxicillin‐clavulanate Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	NR	No studies
AB103 vs placebo Mortality · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 0.34 [0.05, 2.16]	1 study · 43 participants	Very low
AB103 vs placebo Serious adverse events (SAE) · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 1.49 [0.52, 4.27]	1 study · 43 participants	Very low
AB103 vs placebo Survival time · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	NR	No studies
AB103 vs placebo Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	no estimate extracted	NR	No studies
Intravenous immunoglobulin vs placebo Mortality · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane	RR 1.17 [0.42, 3.23]	1 study · 100 participants	Low
Fluocinonide 0.05% vs hydrocortisone 1% Clearing or excellent improvement (after 6 weeks of treatment) · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	1 study · 78 participants	Low
Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	1 study · 58 participants	Moderate
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Clearing or excellent improvement (after 8 weeks of treatment) · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	1 study · 10 participants	Ungraded
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% At least 50% reduction in erythema · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	NR	No studies
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	NR	No studies
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Relapse · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	NR	No studies
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	NR	No studies
R‐salbutamol 0.5% topical cream vs placebo Clearing or excellent improvement · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	1 study · 37 participants	Ungraded
R‐salbutamol 0.5% topical cream vs placebo At least 50% reduction in erythema · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane	no estimate extracted	1 study · 37 participants	Ungraded